Jason Wu, chairman and CEO of Ascletis Pharma, the first biotech company to list on the Hong Kong stock exchange under looser listing rules adopted this year. Photo: Bloomberg

Ascletis Pharma, Asia’s first pre-profit listed biotech, plunges in Hong Kong three days after debut

Analysts warn the fall in drug makers bodes ill for the other unprofitable biotechs queuing up to list

Topic |   HKEX

TOP PICKS

Jason Wu, chairman and CEO of Ascletis Pharma, the first biotech company to list on the Hong Kong stock exchange under looser listing rules adopted this year. Photo: Bloomberg
READ FULL ARTICLE